The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cellmid (CDY) subsidiary, Advangen, has signed a distribution agreement with Tru Beauty Concepts for its anti-aging hair care products, évolis
  • Tru Beauty is a salon distributor that services 40,000 salons across the U.S.
  • Under the agreement, Tru Beauty will sell the évolis range to salons in northeast America for five years
  • Cellmid is up four per cent on the market today and shares are trading for 13 cents per share

Cellmid (CDY) subsidiary, Advangen, has signed a distribution agreement with Tru Beauty Concepts for its anti-aging hair care products, évolis.

Tru Beauty is a salon distributor and national educator, servicing 40,000 salons through the United States.

Under the agreement, Tru Beauty will sell the évolis range to salons in northeast America for five years.

évolis will also be listed on the Salon Interactive portal, which is an e-commerce hub for hair salons across the U.S. This deal is expected to result in significant revenue growth in the U.S. business during the second half of the 2021 financial year.

CEO Maria Halasz says this agreement is a “game-changer.”

“Securing salon distribution will add scale to our U.S. expansion and growth ambitions for the brand,” she added.

The deal comes as consumer health services in the U.S. increased by 51 per cent to $626,000 over FY20.

Cellmid is up four per cent on the market this afternoon and shares are trading for 13 cents per share at 1:26 pm AEST.

cdy by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…